Business Wire

New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting

Del

New real-world and clinical evidence demonstrates that TECFIDERA® (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients with relapsing-remitting multiple sclerosis (RRMS) and affirms its well-characterized safety profile in patients who have had up to nine years of treatment. Biogen (NASDAQ: BIIB) will present these data at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.

“As we continue to gather both clinical and real-world data, evidence shows that TECFIDERA consistently demonstrates strong efficacy in reducing MS disease activity over the long term,” said Ralph Kern, M.D., senior vice president, Worldwide Medical, Biogen. “The findings presented at ECTRIMS confirm the results we observed in the TECFIDERA clinical trial program, further supporting its early use to improve outcomes for people living with MS.”

Comparative Real-World Data Echo Strong Efficacy of TECFIDERA Observed in Clinical Trials
Real-world evidence affirms the positive effects of TECFIDERA treatment observed in clinical trials, and demonstrates effectiveness versus multiple MS therapies.

Using data sourced from the global MSBase registry and propensity score matching, researchers compared relapse rates and discontinuation outcomes in 415 TECFIDERA-treated patients to those treated with another widely-used disease-modifying therapy (fingolimod, teriflunomide, interferon β and glatiramer acetate). MSBase is an ongoing, longitudinal, observational registry that includes data from nearly 40,000 MS patients across 72 countries.

Real-world evidence from the MSBase analysis shows significant benefits with TECFIDERA on time to first relapse relative to interferon β (26%; hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.57, 0.97), glatiramer acetate (28%; HR 0.72; 95% CI 0.54, 0.95) and teriflunomide (34%; HR 0.66; 95% CI 0.45, 0.99). Time to first relapse between TECFIDERA and fingolimod was similar.

“The MSBase registry is one of the largest sources of real-world data, contributed by physicians with the ultimate goal of improving MS quality of care,” said professor Helmut Butzkueven, joint director of the Multiple Sclerosis Service at the Royal Melbourne Hospital and associate professor in the Department of Medicine, University of Melbourne. “When we conducted this comparative effectiveness research, propensity score matching helped ensure the similarity of the patient populations, which strengthened the analysis. The data showed that TECFIDERA significantly reduced the time to first relapse compared to platform therapies and teriflunomide and had comparable efficacy to fingolimod.”

The MSBase analysis also evaluated two secondary endpoints, annualized relapse rate (ARR) and treatment persistence. Longer follow-up of TECFIDERA in the real-world setting will strengthen this analysis and may clarify the effects seen on ARR across treatment groups. An increase of treatment discontinuation with TECFIDERA relative to fingolimod and interferon was also observed. A separate real-world retrospective analysis of TECFIDERA patients presented at ECTRIMS suggests that providing patient coaching can offer a potentially effective means to reduce treatment discontinuations.

Additional efficacy data presented at ECTRIMS include:

  • New U.S. health claims data from a large commercial insurance database, which demonstrate the real-world effectiveness of TECFIDERA compared to other MS therapies, as supported by the MSBase registry. A new analysis of these data also shows consistent results in a subgroup of newly-diagnosed patients.
  • Data from the ongoing Phase 3 ENDORSE study that show the ARR and 24-week confirmed disability progression remained low in newly-diagnosed patients treated with TECFIDERA over a minimum of seven years.

Favorable Benefit-Risk Profile Strengthened by Nine Years of Treatment Data
The safety profile of TECFIDERA remains unchanged and the overall benefit-risk remains favorable, as demonstrated by up to nine years of clinical study results and real-world evidence presented at the congress. Further, the data continue to substantiate current guidance for monitoring absolute lymphocyte counts (ALC) to effectively identify patients at risk of severe and prolonged lymphopenia.

A List of TECFIDERA ECTRIMS Data Presentations Includes:

  • Poster Session 1 – Thursday, 15 September – 15:45-17:00 PM BST
    • Absolute Lymphocyte Count and Lymphocyte Subset Profiles During Long-Term Treatment with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis (P716)
    • Seven-Year Follow-up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P631)
  • Poster Session 2 – Friday, 16 September – 15:30-17:00 PM BST
    • Comparative Analysis of Multiple Sclerosis Outcomes in Dimethyl Fumarate-Treated Patients Relative to Propensity Matched Fingolimod, Interferon, Glatiramer Acetate, or Teriflunomide (P1157)
    • The Potential of Individualized Patient Coaching to Optimize Treatment With Delayed-Release Dimethyl Fumarate: A Retrospective Analysis of Patients With Multiple Sclerosis Treated in a Real-World Setting (P1214)
  • ePosters – Available in ECTRIMS Online Library and App
    • Annual Relapse Rates in Multiple Sclerosis Patients Treated with Different Disease-Modify Therapies – Findings from a Real World Setting (EP1481)
    • Effect of Delayed-Release Dimethyl Fumarate on Lymphocyte Subsets in Patients with Relapsing Multiple Sclerosis: A Retrospective, Multicentre, Observational Study (REALIZE) (EP1495)

About ENDORSE
ENDORSE is an ongoing global, dose-blind, Phase 3 extension study to determine the long-term safety and efficacy of TECFIDERA (240 mg, BID or TID). The study has enrolled 1,738 patients with RRMS who completed the DEFINE or CONFIRM studies. Patients who received two years of TECFIDERA in DEFINE and CONFIRM continued on the same dose (BID or TID) in ENDORSE. Patients who previously received placebo or glatiramer acetate (CONFIRM only) were randomized 1:1 to TECFIDERA BID or TID. Following TECFIDERA approval at a dose of 240 mg BID, all subjects continuing in this study received open-label TECFIDERA 240 mg BID. Patients participating in ENDORSE will be followed for up to eight years.

The primary objective of the study is to evaluate the long-term safety profile of TECFIDERA. Secondary objectives include: long-term efficacy of TECFIDERA on clinical outcomes and MS brain lesions on MRI scans; and effects of TECFIDERA on quality of life measurements.

About TECFIDERA ®
TECFIDERA is an oral therapy for relapsing forms of MS, including relapsing-remitting MS, the most common form of MS. TECFIDERA is currently approved in 24 countries including the United States, the European Union, Canada, Australia and Switzerland. Through a robust clinical trial program and commercial launches starting with the United States in March 2013, more than 215,000 patients have been treated with TECFIDERA worldwide.1

TECFIDERA has been proven to reduce the rate of MS relapses, slow the progression of disability, and the number of MS brain lesions, while demonstrating a favorable benefit-risk profile in a broad range of patients with relapsing forms of MS. 2 In clinical trials, the most common adverse events associated with TECFIDERA were flushing and gastrointestinal (GI) events. Other side effects included a decrease in mean lymphocyte counts during the first year of treatment, which then plateaued. TECFIDERA is contraindicated in patients with a known hypersensitivity to dimethyl fumarate or any of the excipients of TECFIDERA. Rare cases of PML have been seen with TECFIDERA patients in the setting of prolonged moderate to severe lymphopenia.

The efficacy and safety of TECFIDERA have been studied in a large, global clinical program, which includes an ongoing long-term extension study. It is believed that TECFIDERA treats MS by activating the Nrf2 pathway, although its exact mechanism of action is unknown. This pathway provides a way for cells in the body to defend themselves against inflammation and oxidative stress caused by conditions like MS.

For additional important safety information, and the United States full prescribing information, please visit www.tecfidera.com.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

Safe Harbor
This press release includes forward-looking statements, including statements about the benefits of TECFIDERA in MS patients over the long-term. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "will," and other words and terms of similar meaning. You should not place undue reliance on these statements. Drug development and commercialization involve a high degree of risk and only a small number of research and development programs result in commercialization of a product. Factors which could cause actual results to differ materially from our current expectations include the risk that unexpected concerns may arise from additional data or analysis, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of our product labeling, or we may encounter other unexpected hurdles. For more detailed information on the risks and uncertainties associated with our drug development and commercialization activities, please review the Risk Factors section of our most recent annual or quarterly report filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.

1 Combined post-marketing and clinical trials exposure to TECFIDERA as of 30 June 2016.
2 TECFIDERA is approved in the European Union for relapsing-remitting multiple sclerosis.

Contact information

Biogen
MEDIA CONTACT:
Lindsey Smith, +1-781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1-781-464-2442
IR@biogen.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors14.12.2017 21:30Pressemelding

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Executive Chairman John Martin, PhD will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018. Dr. Martin was named Executive Chairman on March 10, 2016, when he was succeeded as CEO by John Milligan, PhD. Dr. Martin served as CEO of Gilead from 1996 to 2016, having joined the company in 1990 as the Vice President of Research and Development. During his time as CEO, he built the company’s portfolio to 24 marketed products with annual revenues of more than $32 billion. “John's scientific and business leadership has been notable for the development of Gilead’s portfolio of HIV and viral hepatitis medicines and commitment to worldwide access for patients. We are all grateful that he will continue to help guide the company as Chairman of the Board,” said Dr. Milligan, Pr

UniPrint Infinity Now Available in Epic App Orchard14.12.2017 19:07Pressemelding

UniPrint.net announced today that UniPrint Infinity software is now available in the Epic App Orchard Marketplace. Users can now take advantage of UniPrint Infinity’s secure release print suite which works with any printer, any device, and in any computing environment. UniPrint Infinity’s PDF-based Healthcare Printing Suite provides industry standard 256-bit data encryption and compression, high availability, archiving, and “follow-the-user” printing, resulting in increased security and compliance in addition to reduced print costs. Implementation of UniPrint Infinity is proven to reduce wait times and help desk calls. By improving workflows for doctors, nurses, and other healthcare providers, UniPrint Infinity allows healthcare staff to focus their attention on their most important task: providing better patient care. “Building upon our recent Imprivata SSO integrati

FINEOS Announces Three New Customers in the Cloud14.12.2017 15:57Pressemelding

FINEOS Corporation, the market leading provider of core systems for Life, Accident and Health (LA&H) insurance, today announced three new customers who have acquired FINEOS as a cloud service. The three new FINEOS customers, based in the US, Sweden and Canada respectively, have licenced FINEOS for their group insurance core processing needs. FINEOS is partnering with Amazon Web Services (AWS), the world’s largest IaaS cloud provider, to deliver the FINEOS Software as a Service (SaaS) offering. FINEOS Insurance Cloud is designed for the specific compliance and security needs of the LA&H industry. With simple subscription pricing, a FastTrack implementation approach, 24 x 7 support and continuous upgrades, the FINEOS Insurance Cloud is the way forward for LA&H insurance core systems. Speaking about the cloud, Gartner has said “By 2020, a Corporate ‘

UniPrint Infinity Now Available in Epic App Orchard14.12.2017 15:52Pressemelding

UniPrint.net announced today that UniPrint Infinity software is now available in the Epic App Orchard Marketplace. Users can now take advantage of UniPrint Infinity’s secure release print suite which works with any printer, any device, and in any computing environment. UniPrint Infinity’s PDF-based Healthcare Printing Suite provides industry standard 256-bit data encryption and compression, high availability, archiving, and “follow-the-user” printing, resulting in increased security and compliance in addition to reduced print costs. Implementation of UniPrint Infinity is proven to reduce wait times and help desk calls. By improving workflows for doctors, nurses, and other healthcare providers, UniPrint Infinity allows healthcare staff to focus their attention on their most important task: providing better patient care. “Building upon our recent Imprivata SSO integrati

Abdullah bin Zayed Honors Winners of the Al Hassan Bin Ali Award 2017 as Part of the Fourth Annual Forum for Promoting Peace in Muslim Societies14.12.2017 15:19Pressemelding

His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, hosted a ceremony to honor the ‘Egyptian Family House’, winner of the Imam Al Hassan bin Ali Award 2017, represented by Dr. Mahmoud Hamdi Zaqzouq, Secretary General, and His Eminence Anba Ermia, Assistant Secretary General. Also present were H.E Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and H.E Shaykh Abdallah Bin Bayyah, President of the Forum for Promoting Peace in Muslim Societies. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005883/en/ Left to right: H.E Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance, H.H Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, H.E Shaykh Abdallah Bin Bayyah, President of the Forum for Promoting Peace in Muslim

Kymeta Announces Commercial Availability of KĀLO™ Mobile Internet Access Services14.12.2017 15:00Pressemelding

Kymeta—the communications company making good on the promise of global, mobile connectivity—and Intelsat S.A. (NYSE:I)—operator of the world’s first globalized network—have announced that Kymeta KĀLO internet access is now available with broad initial geographic coverage. Kymeta is redefining how satellite services are purchased with KĀLO internet services, and making mobile communications as easy to buy as a mobile phone plan. KĀLO internet services, powered by the IntelsatOne® Flex network, deliver broad connectivity when paired with the world’s only commercially available flat panel, electronically-steered satellite terminals from Kymeta as well as other satellite terminal solutions. Kymeta™ KyWay™ terminals and mTennau7 antenna subsystem modules open new markets for the satellite industry and allow organizations that require high-bandwidth mobile internet access to do busine

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom